Wells Fargo & Company Instil Bio, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.4 - $0.63 $44 - $69	110 Added 24.44%	560 $0
Q2 2023 Aug 15, 2023	SELL	$0.51 - $0.67 $6,054 - $7,954	-11,872 Reduced 96.35%	450 $0
Q1 2023 May 12, 2023	BUY	$0.6 - $0.91 $7,393 - $11,213	12,322 New	12,322 $8,000
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.37 $1,860 - $2,948	-400 Reduced 75.33%	131 $1,000
Q2 2022 Aug 12, 2022	BUY	$4.21 - $11.15 $2,235 - $5,920	531 New	531 $2,000
Q1 2022 May 16, 2022	SELL	$8.48 - $18.1 $159,220 - $339,845	-18,776 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.37 - $22.5 $288,587 - $422,460	18,776 New	18,776 $321,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.82B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.